Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens

被引:19
作者
Schwaber, MJ
Cosgrove, SE
Gold, HS
Kaye, KS
Carmeli, Y
机构
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
关键词
D O I
10.3201/eid1001.020663
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In a matched case-control study, we studied the effect of prior receipt of fluoroquinolones on isolation of three third-generation cephalosporin-resistant gram-negative nosocomial pathogens. Two hundred eighty-two cases with a third-generation cephalosporin-resistant pathogen (203 with Enterobacter spp., 50 with Pseudomonas aeruginosa, and 29 with Klebsiella pneumoniae) were matched on length of stay to controls in a 1:2 ratio. Case-patients and controls were similar in age (mean 62 years) and sex (54% male). Variables predicting third-generation cephalosporin resistance were surgery (p = 0.005); intensive care unit stay (p < 0.001); and receipt of a beta-lactam/beta-lactamase inhibitor (p < 0.001), a ureidopenicillin (p = 0.002), or a third-generation cephalosporin (p < 0.001). Receipt of a fluoroquinolone was protective against isolation of a third-generation cephalosporin-resistant pathogen (p = 0.005). Interventional studies are required to determine whether replacing third-generation cephalosporins with fluoroquinolones will be effective in reducing cephalosporin resistance and the effect of such interventions on fluoro-auinolone resistance.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 18 条
[1]   Antibiotic resistance - Squeezing the balloon? [J].
Burke, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (14) :1270-1271
[2]  
Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610
[3]   Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa [J].
Carmeli, Y ;
Troillet, N ;
Karchmer, AW ;
Samore, MH .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) :1127-1132
[4]   Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species [J].
Cosgrove, SE ;
Kaye, KS ;
Eliopoulous, GM ;
Carmeli, Y .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (02) :185-190
[5]   Colonization with broad-spectrum cephalosporin-resistant Gram-negative bacilli in intensive care units during a nonoutbreak period: Prevalence, risk factors, and rate of infection [J].
D'Agata, EMC ;
Venkataraman, L ;
DeGirolami, P ;
Burke, P ;
Eliopoulos, GM ;
Karchmer, AW ;
Samore, MH .
CRITICAL CARE MEDICINE, 1999, 27 (06) :1090-1095
[6]   Molecular epidemiology of acquisition of ceftazidime-resistant gram-negative bacilli in a nonoutbreak setting [J].
DAgata, E ;
Venkataraman, L ;
DeGirolami, P ;
Samore, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (10) :2602-2605
[7]   National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-April 2000, issued June 2000 [J].
Gerberding, J ;
Gaynes, R ;
Horan, T ;
Alonso-Echanove, J ;
Edwards, J ;
Emori, G ;
Fridkin, S ;
Hageman, J ;
Henderson, T ;
Lawton, R ;
Peavy, G ;
Richards, C ;
Tolson, J ;
Wages, J .
AMERICAN JOURNAL OF INFECTION CONTROL, 2000, 28 (06) :429-448
[8]   Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli [J].
Harbarth, S ;
Harris, AD ;
Carmeli, Y ;
Samore, MH .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1462-1468
[9]   Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: A systematic review [J].
Harris, AD ;
Karchmer, TB ;
Carmeli, Y ;
Samore, MH .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (07) :1055-1061
[10]   Mechanisms of fluoroquinolone resistance [J].
Hooper, DC .
DRUG RESISTANCE UPDATES, 1999, 2 (01) :38-55